# Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

> **NCT00068393** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 39 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Renal Cell Carcinoma With Sarcomatoid Features

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Gemcitabine
- **DRUG:** G-CSF (granulocyte-colony stimulating factor)
- **DRUG:** Neulasta

## Key facts

- **NCT ID:** NCT00068393
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02-24
- **Primary completion:** 2009-06
- **Final completion:** 2011-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068393, "Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00068393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*